Show Notes
1. GEM-CESAR and ASCENT Trials: Intensive Treatment Strategy in High-Risk Smoldering Multiple Myeloma
https://ash.confex.com/ash/2022/webprogram/Paper159606.html
https://ash.confex.com/ash/2022/webprogram/Paper168930.html
2. What are the odds of having BMPC≥10% in a person with MGUS? IstopMM answers this question by developing a prediction model.
https://ash.confex.com/ash/2022/webprogram/Paper170166.html
Link to the model: https://istopmm.com/riskmodel/
3. RCT comparing Rd (continuous) vs Rd induction-Mel140-AHCT-R Maintenance in transplant-eligible older adults (60-75 years) with newly diagnosed multiple myeloma
https://ash.confex.com/ash/2022/webprogram/Paper159357.html
4. Talquetamab: Phase 1/2 results from Monumental-1
https://tinyurl.com/kwn9en9m
https://www.nejm.org/doi/full/10.1056/NEJMoa2204591
5. MALDI-TOF Mass Spect for Monoclonal Free Light Chain Assessment: A promising candidate for MRD testing in AL amyloidosis
https://tinyurl.com/yrvjjruv
6. Randomized Phase IV REAL Trial (VMP vs Rd) in New Diagnosed Transplant-Ineligible Myeloma
https://tinyurl.com/bde84xuw
7. Teclistamab-Daratumumab-Lenalidomide combination in earlier lines of therapy: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Study
https://ash.confex.com/ash/2022/webprogram/Paper159711.html
8. Three excellent abstracts from IstopMM:
Is MGUS associated with autoimmune disease?
https://tinyurl.com/5dafcz2w
Is isolated hypercalcemia in a person with MGUS worrisome for transformation into myeloma?
https://tinyurl.com/4tut3rea
Is MGUS associated with CKD?
https://tinyurl.com/34swvkj9
9. Outcome of patients with high-risk cytogenetic abnormalities in a secondary analysis of MASTER and Dara-VRD arm of GRIFFIN trials
https://tinyurl.com/2n78yzfh
10. Surrogacy between PFS and OS in Multiple Myeloma
https://ash.confex.com/ash/2022/webprogram/Paper163855.html
https://pubmed.ncbi.nlm.nih.gov/36495317/
What is Blood Cancer Talks?
This is a podcast on latest advances in the understanding and management of blood cancers. Here, we will bring a wide range of experts within hematologic malignancies to discuss various topics in depth.
Host: Raj Chakraborty, MD from Columbia University, New York, Ashwin Kishtagari, MD, from Vanderbilt University, Nashville, and Edward Cliff, MD, from Harvard University, Boston
Tweet your suggestions and feedback to @rajshekharucms @AshKishtagari @Eddie_Cliff @BloodCancerTalk